Great board here. STSI was torpedoed by a negative

Great board here. STSI was torpedoed by a negative article by Adam Feuerstein, claiming that the results of STSI's recent preliminary human trial were bad. In fact, the poorly written press release apparently mis-stated the results which were very good. Here's an excerpt:

In the release, the Company reported: "After one month of supplementation, CRP levels dropped in 26% of the subjects with diabetes, compared with a drop in CRP levels in 12% of the general trial population of subjects who did not have diabetes." These figures reflected an understatement of the decrease in CRP levels after anatabine supplementation. The correct figures are as follows: 11 of 18 (61%) diabetic subjects on metformin had a CRP reduction, as did 31 of 81 (38%) subjects in the general trial population not taking metformin. Overall, 42 of 99 (42%) subjects had a decrease in CRP after only one month with anatabine supplementation.

The CRP they refer to is C-reactive protein, a marker of systemic inflammation which leads to heart attacks, stroke, and possibly Alzheimers. STSI has numerous trials going on at Johns Hopkins and the Roskamp Clinic in Florida, which specializes in neurological problems.

The other potentially market moving event with this stock is that they have reached a settlement in their long-standing patent infringement suit against R.J. Reynolds, which STSI claimed was infringing their patents. We know that STSI got an up front payment of 5 million bucks but the terms of the settlement are confidential so far. If they have reached a royalty agreement with RAI this could be a huge event for the company. Of course, if the 5 million is the extent of the payment, it could torpedo the stock.

I will say that I have been taking STSI's powerful and side-effect free nutraceutical, Anatabloc, for months and I have found it to be great, as have several friends who I convinced to try it.